泻白散对过敏性哮喘大鼠肺、肠组织形态结构及PI3K和Akt表达水平的影响

doi:10.12300/j.issn.1674-5817.2025.084

实验动物与比较医学 ›› 2026, Vol. 46 ›› Issue (2): 191-204.DOI: 10.12300/j.issn.1674-5817.2025.084

泻白散对过敏性哮喘大鼠肺、肠组织形态结构及PI3K和Akt表达水平的影响

宋静¹^,²^,³, 杨宗统²()(), 李晓晶², 李自发¹, 苏凤云³, 徐东川², 隋在云²()()

^1.山东中医药大学, 济南 250355
^2.山东省中医药研究院中药药理研究所, 济南 250014
^3.山东第一医科大学第二附属医院, 泰安 271000

收稿日期:2025-06-10 修回日期:2025-08-21 出版日期:2026-04-25 发布日期:2026-04-18
通讯作者:
杨宗统（1992—），男，博士，助理研究员，研究方向：中药免疫药理及药效学。E-mail： YangZT2021@163.com。ORCID：0009-0005-5401-7697

隋在云（1964—），女，硕士生导师，研究员，研究方向：中药及其有效成分作用机制及安全性评价。E-mail： zy_505@163.com。

ORCID：0009-0008-4487-2317
作者简介:宋静（1987—），女，硕士研究生，研究方向：中药及其有效成分作用机制及安全性评价。E-mail：583023072@qq.com
基金资助:
山东省重大科技创新工程项目“基于网络药理学技术对泻白散药效成分-哮喘靶标关联性的探索研究”(2018CXGC1301);山东省中医药科技项目“基于PI3K-Akt信号通路探讨经典名方泻白散治疗过敏性哮喘的肠道黏膜免疫作用机制”(2021Q126);山东省中医药研究院科研孵化基金项目“基于PI3K-Akt信号通路的过敏性哮喘大鼠‘肺与大肠相表里’免疫机制研究”(2021SACM-1)

Effects of Xiebai San on the Morphological Structures of Lung and Intestinal Tissues and Expression Levels of PI3K and Akt in Rats with Allergic Asthma

SONG Jing¹^,²^,³, YANG Zongtong²()(), LI Xiaojing², LI Zifa¹, SU Fengyun³, XU Dongchuan², SUI Zaiyun²()()

^1.Shandong University of Traditional Chinese Medicine, Jinan 250355, China
^2.Institute of Pharmacology of Traditional Chinese Medicine, Shandong Academy of Traditional Chinese Medicine, Jinan 250014, China
^3.The Second Affiliated Hospital of Shandong First Medical University, Tai'an 271000, China

Received:2025-06-10 Revised:2025-08-21 Published:2026-04-25 Online:2026-04-18
Contact: YANG Zongtong (ORCID: 0009-0005-5401-7697), E-mail: YangZT2021@163.com
SUI Zaiyun (ORCID: 0009-0008-4487-2317), E-mail: zy_505@163.com

摘要/Abstract

摘要：

目的探讨泻白散对过敏性哮喘大鼠呼吸道和肠道黏膜免疫的作用机制。方法 40只雄性SD大鼠按体重随机分为空白组、模型组、阳性药组和泻白散组，每组10只。模型组、阳性药组和泻白散组均使用卵清蛋白致敏法建立大鼠过敏性哮喘模型。自雾化激发期（第21天）开始，各组同时进行灌胃干预，即阳性药组大鼠灌胃地塞米松（0.068 mg/kg），泻白散组大鼠灌胃泻白散药液（2 g/mL，11.3 mL/kg），空白组与模型组大鼠灌胃等体积生理盐水，每日1次，连续14 d。将大鼠安乐死后，采集各组大鼠肺、肠组织，经HE染色观察组织病理学变化；透射电子显微镜观察组织超微病理结构；免疫组织化学法观察磷脂酰肌醇3-激酶（phosphatidylinositol 3-kinase，PI3K）和蛋白激酶B（protein kinase B，Akt）蛋白阳性面积。提取大鼠肺、肠组织中的总蛋白和总RNA，采用蛋白质印迹法和实时荧光定量PCR法分别检测PI3K和Akt基因的蛋白和mRNA表达水平。结果组织病理学结果显示，与空白组相比，模型组大鼠出现肺泡性肺气肿伴炎性细胞浸润，以及肠黏膜损伤伴炎性细胞浸润；肺组织细胞结构被破坏，细胞器数量减少，但肠超微结构病变较轻。与模型组相比，泻白散组大鼠肺组织病变程度较低，偶见肺泡壁损伤伴少量炎性细胞浸润，肠黏膜结构改善，腺体排列整齐，疏松、浸润等病理改变均见好转；肺组织细胞结构比较完整，病变程度减轻，肠组织无超微结构病理变化。免疫组织化学和蛋白质印迹结果显示，与空白组相比，模型组大鼠肺、肠组织中PI3K和Akt特异性阳性反应面积均显著增大（均P<0.001），PI3K和Akt蛋白表达量也均显著增加（均P<0.05）；与模型组相比，泻白散组大鼠肺组织中Akt蛋白阳性面积显著减少（P<0.001），肠组织中PI3K阳性面积显著减少（P<0.000 1），同时肺、肠组织中PI3K和Akt蛋白表达量均显著减少（均P<0.01）。实时荧光定量PCR结果显示，与空白组相比，模型组大鼠肺、肠组织中PI3K、Akt基因的mRNA表达量均显著增加（均P<0.05）；与模型组相比，泻白散组大鼠肺、肠组织中PI3K、Akt基因的mRNA表达量均显著减少（均P<0.05）。结论泻白散可通过抑制过敏性哮喘大鼠肺、肠组织中PI3K-Akt信号通路关键核酸和蛋白表达，改善肺组织形态结构，保护肠道黏膜完整性，并调节肠道黏膜免疫功能等机制，发挥对过敏性哮喘大鼠的保护作用。

关键词: 泻白散, 哮喘, 黏膜免疫, PI3K-Akt信号通路, 大鼠

Abstract:

Objective To investigate the mechanism by which Xiebai San regulates respiratory tract and intestinal mucosal immunity in rats with allergic asthma. Methods Forty male SD rats were randomly divided into four groups based on body weight: control group, model group, positive control group, and Xiebai San group. The model group, positive control group, and Xiebai San group were sensitized with ovalbumin to establish a rat model of allergic asthma. From day 21 (the aerosol challenge phase), each group received daily gavage interventions simultaneously: the positive control group was administered dexamethasone (0.068 mg/kg), the Xiebai San group received Xiebai San solution (2 g/mL, 11.3 mL/kg), while the control and model groups were given an equal volume of normal saline, once daily for 14 consecutive days. After euthanasia, lung and intestinal tissues were collected. Hematoxylin and eosin staining was used to observe histopathological changes. Transmission electron microscopy was employed to examine tissue ultrastructure. Immunohistochemistry was applied to detect the positive reaction areas of phosphatidyl-inositol 3-kinase (PI3K) and protein kinase B (Akt) proteins. Total protein and total RNA were extracted from lung and intestinal tissues, then the protein and mRNA expression levels of PI3K and Akt genes were detected by Western blotting and real-time quantitative PCR, respectively. Results Histopathological results showed alveolar emphysema accompanied by inflammatory cell infiltration, and intestinal mucosal injury with inflammatory cell infiltration in the model group as compared with the control group; the cellular structure of lung tissues was disrupted in the model group, with reduced organelles, while the ultrastructural lesions in the intestine were relatively mild. Compared with the model group, Xiebai San group exhibited milder pathological changes in lung tissues, with occasional alveolar wall damage and a small amount of inflammatory cell infiltration; the intestinal mucosal structure was improved, glands were arranged regularly, and pathological changes such as tissue loosening and inflammatory infiltration were alleviated; the cellular structure of lung tissues was relatively intact with reduced severity of lesions, and no ultrastructural pathological changes were observed in intestinal tissues. Immunohistochemistry and Western blotting results showed that compared with the control group, the specific positive reaction areas of PI3K and Akt in lung and intestinal tissues were significantly increased in the model group (all P<0.001); meanwhile, the protein expression levels of PI3K and Akt were significantly upregulated (all P<0.05). Compared with the model group, the positive area of Akt protein in lung tissue was significantly reduced in the Xiebai San group (P<0.001), and the positive area of PI3K in intestinal tissue was also significantly decreased (P<0.000 1). Additionally, the protein expression levels of PI3K and Akt in lung and intestinal tissues were significantly downregulated (all P<0.01). Real-time quantitative PCR results showed that compared with the control group, the mRNA expression levels of PI3K and Akt genes in lung and intestinal tissues were significantly elevated in the model group (all P<0.05). Compared with the model group, the mRNA expression levels of PI3K and Akt genes in lung and intestinal tissues were significantly reduced in the Xiebai San group (all P<0.05). Conclusion Xiebai San exerts protective effects on rats with allergic asthma by inhibiting the expression of key nucleic acids and proteins in the PI3K-Akt signaling pathway in lung and intestinal tissues, improving the morphological structure of lung tissue, and maintaining intestinal mucosal integrity, and regulating intestinal mucosal immune function.

Key words: Xiebai San, Asthma, Mucosal immunity, PI3K-Akt signaling pathway, Rats

中图分类号:

Q95-33

宋静,杨宗统,李晓晶,等. 泻白散对过敏性哮喘大鼠肺、肠组织形态结构及PI3K和Akt表达水平的影响[J]. 实验动物与比较医学, 2026, 46(2): 191-204. DOI: 10.12300/j.issn.1674-5817.2025.084.

SONG Jing,YANG Zongtong,LI Xiaojing,et al. Effects of Xiebai San on the Morphological Structures of Lung and Intestinal Tissues and Expression Levels of PI3K and Akt in Rats with Allergic Asthma[J]. Laboratory Animal and Comparative Medicine, 2026, 46(2): 191-204. DOI: 10.12300/j.issn.1674-5817.2025.084.

图/表 9

表1 引物设计与合成

Table 1 Primer design and synthesis

基因名称 Gene name	引物序列（5'→3'） Primer sequence (5'→3')	产物大小/bp Product size/bp
PI3K	F: GCGTGACATGTAGGCTCTCG	349
PI3K	R: GGGCAGTGCTGGTGGAT	349
Akt	F: CCGCCTGATCAAGTTCTCCT	118
Akt	R: TTCAGATGATCCATGCGGGG	118
β-actin	F: CGCAGCCACTGTCGAGTC	96
β-actin	R: GTCATCCATGGCGAACTGGT	96

表2 PCR反应程序

Table 2 PCR cycling program

程序 Program	温度/℃ Temperature/℃	时间 Time
预变性 Initial denaturation	95	3 min
扩增 Amplification	95	20 s
45个循环 45 cycles	61	15 s
熔解曲线 Melting curve	95	5 s
	65	1 min
	97	10 s

表3 泻白散给药后大鼠肺组织McGuigan病理评分的比较 (n=8,

x ˉ

±s)

Table 3 Comparison of McGuigan pathological scores in lung tissues of rats after Xiebai San administration

xˉ±s)
">

组别 Group	肺气肿积分 Pulmonary emphysema score	肺充/出血积分 Pulmonary congestion/bleeding score	肺间质增厚积分 Pulmonary interstitial thickening score	炎细胞浸润积分 Inflammatory cell infiltration score	总积分 Total score
空白组 Control group	0.00±0.00	0.67±0.58	0.67±0.58	0.67±0.58	2.00±1.00
模型组 Model group	2.56±0.53^∗∗	1.56±0.53^∗	1.89±0.60^∗	1.89±0.78^∗	7.89±1.05^∗∗
阳性药组 Positive control group	1.86±0.69^##	1.43±0.53	2.14±0.38	1.57±0.53	7.00±1.15
泻白散组 Xiebai San group	1.46±0.88^##	1.54±0.52	1.46±0.52	1.46±0.52	5.92±1.26^#

表3 泻白散给药后大鼠肺组织McGuigan病理评分的比较 (n=8, $x ˉ$ ±s)

Table 3 Comparison of McGuigan pathological scores in lung tissues of rats after Xiebai San administration

组别 Group	肺气肿积分 Pulmonary emphysema score	肺充/出血积分 Pulmonary congestion/bleeding score	肺间质增厚积分 Pulmonary interstitial thickening score	炎细胞浸润积分 Inflammatory cell infiltration score	总积分 Total score
空白组 Control group	0.00±0.00	0.67±0.58	0.67±0.58	0.67±0.58	2.00±1.00
模型组 Model group	2.56±0.53^∗∗	1.56±0.53^∗	1.89±0.60^∗	1.89±0.78^∗	7.89±1.05^∗∗
阳性药组 Positive control group	1.86±0.69^##	1.43±0.53	2.14±0.38	1.57±0.53	7.00±1.15
泻白散组 Xiebai San group	1.46±0.88^##	1.54±0.52	1.46±0.52	1.46±0.52	5.92±1.26^#

注：HE染色观察泻白散给药对哮喘大鼠肺（A）、肠（B）组织病理变化的影响（n=8）。图A自左至右依次为×0.8（比例尺3 mm）、×10（比例尺200 μm）、×20（比例尺100 μm）；图B自左至右依次为×1.5（比例尺2 mm）、×10（比例尺200 μm）、×20（比例尺100 μm）。方框与黑色圆圈标示的区域见后续放大视野。图A中红色圆圈区域表示肺间质增宽、细胞浸润，小血管及间质充血；血管周围见单核细胞、淋巴细胞炎性浸润。图B中红色圆圈区域表示肠黏膜损伤，肠黏膜固有层内见淋巴细胞、单核细胞浸润，偶见嗜酸性粒细胞。
">

图1 泻白散给药对哮喘大鼠肺、肠组织病理变化的影响
注：HE染色观察泻白散给药对哮喘大鼠肺（A）、肠（B）组织病理变化的影响（n=8）。图A自左至右依次为×0.8（比例尺3 mm）、×10（比例尺200 μm）、×20（比例尺100 μm）；图B自左至右依次为×1.5（比例尺2 mm）、×10（比例尺200 μm）、×20（比例尺100 μm）。方框与黑色圆圈标示的区域见后续放大视野。图A中红色圆圈区域表示肺间质增宽、细胞浸润，小血管及间质充血；血管周围见单核细胞、淋巴细胞炎性浸润。图B中红色圆圈区域表示肠黏膜损伤，肠黏膜固有层内见淋巴细胞、单核细胞浸润，偶见嗜酸性粒细胞。

Figure 1 Effects of Xiebai San on histopathological changes in lung and intestinal tissues of asthmatic rats
Note： Effects of Xiebai San on histopathological changes in lung （A） and intestinal （B） tissues of asthmatic rats （n=8） were detected by HE staining. In figure A， from left to right， the images are presented at magnifications of ×0.8 （scale bar： 3 mm）， ×10 （scale bar： 200 μm）， and ×20 （scale bar： 100 μm）； In Figure B， from left to right， the images are presented at magnifications of ×1.5（scale bar： 2 mm）， ×10（scale bar： 200 μm）， and ×20（scale bar： 100 μm）. Boxed and black-circled areas are shown at higher magnification in subsequent panels. Red-circled areas in Figure A： widened pulmonary interstitium with cellular infiltration， congestion of small vessels and interstitium； inflammatory infiltration of monocytes and lymphocytes was observed around the blood vessels. Red-circled areas in Figure B： intestinal mucosal injury； infiltration of lymphocytes and monocytes， occasionally eosinophils， were found in the lamina propria of the intestinal mucosa.

注：透射电子显微镜观察泻白散给药对哮喘大鼠肺（A）、肠（B）组织超微病理结构的影响（n=3）。图A自左至右依次为×2 000（比例尺5 μm）、×6 000（比例尺2 μm）；图B自左至右依次为×3 000（比例尺5 μm）、×6 000（比例尺2 μm）。方框标示的区域见后续放大视野。
">

图2 泻白散给药对哮喘大鼠肺、肠组织超微病理结构的影响
注：透射电子显微镜观察泻白散给药对哮喘大鼠肺（A）、肠（B）组织超微病理结构的影响（n=3）。图A自左至右依次为×2 000（比例尺5 μm）、×6 000（比例尺2 μm）；图B自左至右依次为×3 000（比例尺5 μm）、×6 000（比例尺2 μm）。方框标示的区域见后续放大视野。

Figure 2 Effects of Xiebai San administration on ultrastructural pathology of lung and intestinal tissues in asthmatic rats
Note： The effects of Xiebai San administration on the ultrastructural pathology of lung （A） and intestinal （B） tissues in asthmatic rats were observed by transmission electron microscopy （n=3）. In Figure A， from left to right， the images are presented at magnifications of ×2 000（scale bar： 5 μm）， ×6 000 （scale bar： 2 μm）； In Figure B， from left to right， the images are presented at magnifications of ×3 000 （scale bar： 5 μm）， ×6 000 （scale bar： 2 μm）. Boxed areas are shown at higher magnification in subsequent panels.

注：免疫组织化学法检测泻白散给药对哮喘大鼠肺组织中PI3K（A）、Akt（B）蛋白分布的影响（n=8）；图C与图D分别为PI3K、Akt蛋白分布的量化散点图（每组随机抽取3个切片，每个切片随机选取10个视野，每个点代表1个数据）。与空白组相比，^???P<0.001，^????P<0.000 1；与模型组相比，^???P<0.001，^????P<0.000 1；ns表示差异无统计学意义。图A、B自左至右依次为×10（比例尺250 μm）、×20（比例尺100 μm）。方框标示的区域见后续放大视野。PI3K，磷脂酰肌醇3-激酶；Akt，蛋白激酶B。
">

图3 泻白散给药对哮喘大鼠肺组织中PI3K、Akt蛋白分布的影响
注：免疫组织化学法检测泻白散给药对哮喘大鼠肺组织中PI3K（A）、Akt（B）蛋白分布的影响（n=8）；图C与图D分别为PI3K、Akt蛋白分布的量化散点图（每组随机抽取3个切片，每个切片随机选取10个视野，每个点代表1个数据）。与空白组相比，^???P<0.001，^????P<0.000 1；与模型组相比，^???P<0.001，^????P<0.000 1；ns表示差异无统计学意义。图A、B自左至右依次为×10（比例尺250 μm）、×20（比例尺100 μm）。方框标示的区域见后续放大视野。PI3K，磷脂酰肌醇3-激酶；Akt，蛋白激酶B。

Figure 3 Effects of Xiebai San administration on PI3K and Akt protein distribution in lung tissues of asthmatic rats
Note： Effects of Xiebai San administration on the distribution of PI3K （A） and Akt （B） proteins in lung tissues of asthmatic rats were detected by immunohistochemistry （n=8）； Figures C and D show quantitative scatter plots of PI3K and Akt protein distribution， respectively （three randomly selected sections per group， ten fields of view randomly selected per section， each point represents one data point）. Compared with the control group， ^???P<0.001，^????P<0.000 1； Compared with the model group， ^???P<0.001，^????P<0.000 1； ns indicates no significant difference. In Figures A and B， from left to right， the images are presented at magnifications of ×10（scale bar： 250 μm）， ×20（scale bar： 100 μm）. Boxed areas are shown at higher magnification in subsequent panels. PI3K， phosphatidylinositol 3-kinase； Akt， protein kinase B.

注：免疫组织化学法检测泻白散给药对哮喘大鼠肠组织中PI3K（A）、Akt（B）蛋白分布的影响（n=8）；图C与图D分别为PI3K、Akt蛋白分布的量化散点图（每组随机抽取3个切片，每个切片随机选取10个视野，每个点代表1个数据）。与空白组相比，^????P<0.000 1；与模型组相比，^?P<0.05，^??P<0.01，^????P<0.000 1；ns表示差异无统计学意义。图A、B自左至右依次为×10（比例尺250 μm）、×20（比例尺100 μm）。方框标示的区域见后续放大视野。PI3K，磷脂酰肌醇3-激酶；Akt，蛋白激酶B。
">

图4 泻白散给药对哮喘大鼠肠组织中PI3K、Akt蛋白分布的影响
注：免疫组织化学法检测泻白散给药对哮喘大鼠肠组织中PI3K（A）、Akt（B）蛋白分布的影响（n=8）；图C与图D分别为PI3K、Akt蛋白分布的量化散点图（每组随机抽取3个切片，每个切片随机选取10个视野，每个点代表1个数据）。与空白组相比，^????P<0.000 1；与模型组相比，^?P<0.05，^??P<0.01，^????P<0.000 1；ns表示差异无统计学意义。图A、B自左至右依次为×10（比例尺250 μm）、×20（比例尺100 μm）。方框标示的区域见后续放大视野。PI3K，磷脂酰肌醇3-激酶；Akt，蛋白激酶B。

Figure 4 Effects of Xiebai San administration on PI3K and Akt protein distribution in intestinal tissues of asthmatic rats
Note： Effects of Xiebai San administration on the distribution of PI3K （A） and Akt （B） proteins in intestinal tissues of asthmatic rats were detected by immunohistochemistry （n=8）； Figures C and D show quantitative scatter plots of PI3K and Akt protein distribution， respectively （three randomly selected sections per group， ten fields of view randomly selected per section， each point represents one data point）. Compared with the control group， ^????P<0.000 1； Compared with the model group， ^?P<0.05， ^??P<0.01， ^????P<0.000 1； ns indicates no significant difference. In Figures A and B， from left to right， the images are presented at magnifications of ×10（scale bar： 250 μm）， ×20（scale bar： 100 μm）. Boxed areas are shown at higher magnification in subsequent panels. PI3K， phosphatidylinositol 3-kinase； Akt， protein kinase B.

注：蛋白质印迹法检测泻白散给药对哮喘大鼠肺（A）、肠（B）组织中PI3K、Akt蛋白表达的影响；图C与图E分别为肺组织中PI3K与Akt蛋白表达的量化图（与空白组相比，^??P<0.01；与模型组相比，^??P<0.01；ns表示差异无统计学意义，n=3）；图D与图F分别为肠组织中PI3K与Akt蛋白表达的量化图（与空白组相比，^?P<0.05，^???P<0.001；与模型组相比，^??P<0.01，^???P<0.001；n=3）。PI3K，磷脂酰肌醇3-激酶；Akt，蛋白激酶B；β-actin，β-肌动蛋白。
">

图5 泻白散给药对哮喘大鼠肺、肠组织PI3K、Akt蛋白表达的影响
注：蛋白质印迹法检测泻白散给药对哮喘大鼠肺（A）、肠（B）组织中PI3K、Akt蛋白表达的影响；图C与图E分别为肺组织中PI3K与Akt蛋白表达的量化图（与空白组相比，^??P<0.01；与模型组相比，^??P<0.01；ns表示差异无统计学意义，n=3）；图D与图F分别为肠组织中PI3K与Akt蛋白表达的量化图（与空白组相比，^?P<0.05，^???P<0.001；与模型组相比，^??P<0.01，^???P<0.001；n=3）。PI3K，磷脂酰肌醇3-激酶；Akt，蛋白激酶B；β-actin，β-肌动蛋白。

Figure 5 Effects of Xiebai San administration on PI3K and Akt protein expression in lung and intestinal tissues of asthmatic rats
Note： Effects of Xiebai San administration on PI3K and Akt protein expression in lung （A） and intestinal （B） tissues of asthmatic rats were detected by Western blotting； Figures C and E show quantitative analysis of PI3K and Akt protein expression in lung tissues， respectively （compared with the control group， ^??P<0.01； compared with the model group， ^??P<0.01； ns indicates no significant difference， n=3）； Figures D and F show quantitative analysis of PI3K and Akt protein expression in intestinal tissues， respectively （compared with the control group， ^?P<0.05， ^???P<0.001； compared with the model group， ^??P<0.01， ^???P<0.001； n=3）. PI3K， phosphatidylinositol 3-kinase； Akt， protein kinase B.

注：实时荧光定量PCR检测泻白散给药对哮喘大鼠肺组织中PI3K（A）、Akt（B）mRNA表达的影响，以及泻白散给药对哮喘大鼠肠组织中PI3K（C）、Akt（D）mRNA表达的影响。与空白组相比，^?P<0.05，^??P<0.01，^???P<0.001；与模型组相比，^?P<0.05，^??P<0.01，^???P<0.001；ns表示差异无统计学意义，n=3。PI3K，磷脂酰肌醇3-激酶；Akt，蛋白激酶B。
">

图6 泻白散给药对哮喘大鼠肺、肠组织PI3K、Akt基因表达的影响
注：实时荧光定量PCR检测泻白散给药对哮喘大鼠肺组织中PI3K（A）、Akt（B）mRNA表达的影响，以及泻白散给药对哮喘大鼠肠组织中PI3K（C）、Akt（D）mRNA表达的影响。与空白组相比，^?P<0.05，^??P<0.01，^???P<0.001；与模型组相比，^?P<0.05，^??P<0.01，^???P<0.001；ns表示差异无统计学意义，n=3。PI3K，磷脂酰肌醇3-激酶；Akt，蛋白激酶B。

Figure 6 Effects of Xiebai San administration on PI3K and Akt gene expression in lung and intestinal tissues of asthmatic rats
Note： Effects of Xiebai San administration on mRNA expression of PI3K （A） and Akt （B） in lung tissues of asthmatic rats were detected by real-time quantitative PCR. Effects on mRNA expression of PI3K （C） and Akt （D） in intestinal tissues were detected by real-time quantitative PCR. Compared with the control group， ^?P<0.05， ^??P<0.01， ^???P<0.001； compared with the model group， ^?P<0.05， ^??P<0.01， ^???P<0.001； ns indicates no significant difference， n=3. PI3K， phosphatidylinositol 3-kinase； Akt， protein kinase B.

参考文献 30

[1]	任雪交, 黄巍, 邱菲菲, 等. 支气管哮喘动物模型研究的文献分析与评价[J]. 实验动物与比较医学, 2022, 42(1): 74-80. DOI:10.12300/j.issn.1674-5817.2021.044 .
	REN X J, HUANG W, QIU F F, et al. Progress in animal models for bronchial asthma[J]. Lab Anim Comp Med, 2022, 42(1): 74-80. DOI:10.12300/j.issn.1674-5817.2021.044 .
[2]	罗世雄, 张赛, 陈慧. 常见哮喘动物模型的建立方法与评价研究进展[J]. 实验动物与比较医学, 2025, 45(2): 167-175. DOI:10.12300/j.issn.1674-5817.2024.120 .
	LUO S X, ZHANG S, CHEN H. Research progress in establishment and evaluation of common asthma animal models[J]. Lab Anim Comp Med, 2025, 45(2): 167-175. DOI:10.12300/j.issn.1674-5817.2024.120 .
[3]	兰露莎, 赵兵兵, 杨红宇, 等. 氧化苦参碱对小鼠哮喘模型保护作用的初步研究[J]. 实验动物与比较医学, 2017, 37(4): 320-323. DOI:10.3969/j.issn.1674-5817.2017.04.013 .
	LAN L S, ZHAO B B, YANG H Y, et al. The protective effect of oxymatrine on asthma mice[J]. Lab Anim Comp Med, 2017, 37(4): 320-323. DOI:10.3969/j.issn.1674-5817.2017.04.013 .
[4]	AN J, LIU Y Q, WANG Y Q, et al. The role of intestinal mucosal barrier in autoimmune disease: a potential target[J]. Front Immunol, 2022, 13:871713. DOI:10.3389/fimmu.2022.871713 .
[5]	CERVANTES-GARCÍA D, JIMÉNEZ M, RIVAS-SANTIAGO C E, et al. Lactococcus lactis NZ9000 prevents asthmatic airway inflammation and remodelling in rats through the improvement of intestinal barrier function and systemic TGF-β production[J]. Int Arch Allergy Immunol, 2021, 182(4):277-291. DOI:10.1159/000511146 .
[6]	洪天一. 蝎黄解痉治哮颗粒影响NF-κB和HIF-1α信号传导通路治疗哮喘的调控机制[D]. 长春: 长春中医药大学, 2020. DOI: 10.26980/d.cnki.gcczc.2020.000459 .
	HONG T Y. Regulatory mechanism of Xiehuang Jiezhuan Zhixiao granules on the NF-κB and HIF-1α signaling pathways in the treatment of asthma[D]. Changchun: Changchun University of Chinese Medicine, 2020. DOI: 10.26980/d.cnki.gcczc.2020.000459 .
[7]	马兰兰, 陈玲, 王琴, 等. 肺通气功能正常的儿童支气管哮喘控制情况及急性发作随访的研究[J]. 中国当代儿科杂志, 2024, 26(5): 476-480. DOI:10.7499/j.issn.1008-8830.2311149 .
	MA L L, CHEN L, WANG Q, et al. Control status and follow-up of acute attacks in children with bronchial asthma with normal pulmonary ventilation function[J]. Chin J Contemp Pediatr, 2024, 26(5): 476-480. DOI:10.7499/j.issn.1008-8830.2311149 .
[8]	丁云录, 郑明昱, 南敏伦, 等. 基于ERK信号通路探讨鹿茸大补汤颗粒对哮喘缓解期豚鼠的调控及作用机制[J]. 中国老年学杂志, 2023, 43(21):5309-5313. DOI:10.3969/j.issn.1005-9202.2023.21.054 .
	DING Y L, ZHENG M Y, NAN M L, et al. Based on ERK signal pathway, this paper discusses the regulation and mechanism of Lulong Dabutang Granule on guinea pigs with asthma in remission stage[J]. Chin J Gerontol, 2023, 43(21):5309-5313. DOI:10.3969/j.issn.1005-9202.2023.21.054 .
[9]	李玉丽, 易腾达, 谭志强, 等. 经典名方泻白散的源流及古今应用考究[J]. 中国实验方剂学杂志, 2021, 27(4):168-174. DOI:10.13422/j.cnki.syfjx.20202328 .
	LI Y L, YI T D, TAN Z Q, et al. Literature research on origin and application of classical prescription xiebaisan[J]. Chin J Exp Tradit Med Formulae, 2021, 27(4):168-174. DOI:10.13422/j.cnki.syfjx.20202328 .
[10]	刘凌志, 梁敏兰, 郭栋伟. 黄芩泻白散对支气管哮喘小鼠的治疗作用及Wnt/β-catenin信号轴的影响[J]. 湖南中医杂志, 2025, 41(6):140-146. DOI:10.16808/j.cnki.issn1003-7705.2025.06.028 .
	LIU L Z, LIANG M L, GUO D W. Therapeutic effect of Huangqin Xiebai powder on rats with bronchial asthma and its effect on the Wnt/β-catenin signaling axis[J]. Hunan J Tradit Chin Med, 2025, 41(6):140-146. DOI:10.16808/j.cnki.issn1003-7705.2025.06.028 .
[11]	张天柱, 张景龙, 樊湘泽, 等. 泻白散对小鼠过敏性哮喘气道炎症的作用及机制[J]. 中国实验方剂学杂志, 2014, 20(20):173-177. DOI:10.13422/j.cnki.syfjx.2014200173 .
	ZHANG T Z, ZHANG J L, FAN X Z, et al. Effects and its mechanism of Xiebai San on allergic airway inflammation in asthma mouse[J]. Chin J Exp Tradit Med Formulae, 2014, 20(20):173-177. DOI:10.13422/j.cnki.syfjx.2014200173 .
[12]	JUTEL M, MOSNAIM G S, BERNSTEIN J A, et al. The One Health approach for allergic diseases and asthma[J]. Allergy, 2023, 78(7):1777-1793. DOI:10.1111/all.15755 .
[13]	JOHNSON C C, OWNBY D R. The infant gut bacterial microbiota and risk of pediatric asthma and allergic diseases[J]. Transl Res, 2017, 179:60-70. DOI:10.1016/j.trsl.2016.06.010 .
[14]	杨阳, 张桂信, 杨琦, 等. 从肠-肺轴相关微环境角度诠释中医"肺与大肠相表里"的新内涵[J]. 中国中西医结合外科杂志, 2025, 31(02): 295-299. DOI:10.3969/j.issn.1007-6948.2025.02.027 .
	YANG Y, ZHANG G X, YANG Q, et al. Interpretation of the new connotation of "lung and large intestine are exterior and interior" in traditional Chinese medicine from the perspective of microenvironment related to intestine-lung axis[J]. Chin J Surg Integr Tradit West Med, 2025, 31(2): 295-299. DOI:10.3969/j.issn.1007-6948.2025.02.027 .
[15]	刘寻, 周婷婷, 朱紫冰, 等. 槟榔碱通过上调PI3K/Akt/mTOR信号通路促进口腔黏膜下纤维化的体内外实验研究[J]. 中国临床药理学与治疗学, 2025, 30(07): 865-875. DOI:10.12092/j.issn.1009-2501.2025.07.001 .
	LIU X, ZHOU T T, ZHU Z B, et al. Arecoline promotes oral submucous fibrosis by upregulating PI3K/Akt/mTOR signaling pathway in vivo and in vitro [J]. Chin J Clin Pharmacol Ther, 2025, 30(07): 865-875. DOI:10.12092/j.issn.1009-2501.2025.07.001 .
[16]	YAO T, WU Y H, FU L Y, et al. Christensenellaceae minuta modulates epithelial healing via PI3K-AKT pathway and macrophage differentiation in the colitis[J]. Microbiol Res, 2024, 289:127927. DOI:10.1016/j.micres.2024.127927 .
[17]	ACOSTA-MARTINEZ M, CABAIL M Z. The PI3K/Akt pathway in meta-inflammation[J]. Int J Mol Sci, 2022, 23(23):15330. DOI:10.3390/ijms232315330 .
[18]	徐东川. 基于网络药理学方法研究泻白散治疗哮喘的作用机制[D]. 济南: 山东中医药大学, 2022. DOI:10.27282/d.cnki.gsdzu.2022.000841 .
	XU D C. Investigating the mechanism of Xie Bai San in the treatment of asthma using network pharmacology methods[D]. Jinan: Shandong University of Traditional Chinese Medicine, 2022. DOI:10.27282/d.cnki.gsdzu.2022.000841 .
[19]	MCGUIGAN R M, MULLENIX P, NORLUND L L, et al. Acute lung injury using oleic acid in the laboratory rat: establishment of a working model and evidence against free radicals in the acute phase[J]. Curr Surg, 2003, 60(4):412-417. DOI:10.1016/S0149-7944(02)00775-4 .
[20]	覃芳芳, 丘琴, 韦红杏, 等. 泻白散的研究进展及质量标志物(Q-Marker)预测分析[J]. 中华中医药学刊, 2025, 43(11): 155-161. DOI:10.13193/j.issn.1673-7717.2025.11.031 .
	QIN F F, QIU Q, WEI H X, et al. Research progress of Xiebai Powder and prediction analysis of quality markers (Q-markers)[J]. Chin Arch Tradit Chin Med, 2025, 43(11): 155-161. DOI:10.13193/j.issn.1673-7717.2025.11.031 .
[21]	LAMPIASI N. Macrophage polarization: learning to manage it 2.0[J]. Int J Mol Sci, 2023, 24(24):17409. DOI: 10.3390/ijms242417409 .
[22]	张会敏, 杨宗统, 苏本正, 等. 高效液相色谱指纹图谱评价泻白散及其3种单味药内在质量[J]. 化学分析计量, 2021, 30(9): 48-53. DOI:10.3969/j.issn.1008 –6145.2021.09.011.
	ZHANG H M, YANG Z T, SU B Z, et al. Evaluation of internal quality of Xiebai powder and its three single herbs by HPLC fingerprint[J]. Chem Anal Meterage, 2021, 30(9): 48-53. DOI:10.3969/j.issn.1008 –6145.2021.09.011.
[23]	徐东川, 刘瑾, 李晓晶, 等. 泻白散大鼠体内入血成分研究[J]. 中国药房, 2022, 33(1):38-45. DOI:10.6039/j.issn.1001-0408.2022.01.07 .
	XU D C, LIU J, LI X J, et al. Study on absorbed components of Xiebai powder in rat blood[J]. China Pharm, 2022, 33(1):38-45. DOI:10.6039/j.issn.1001-0408.2022.01.07 .
[24]	杨宗统, 徐东川, 刘瑾, 等. 基于非靶向代谢组学和肠道菌群探究经典名方泻白散对过敏性哮喘大鼠的保护作用[J]. 中国实验动物学报, 2024, 32(2): 177-189. DOI:10.3969/j.issn.1005-4847.2024.02.005 .
	YANG Z T, XU D C, LIU J, et al. Protective effect of Xiebaisan on allergic asthma in rats based on non-targeted metabolomics and intestinal bacterial flora[J]. Acta Lab Anim Sci Sin, 2024, 32(2): 177-189. DOI:10.3969/j.issn.1005-4847.2024.02.005 .
[25]	WANG J, HE M, YANG M, et al. Gut microbiota as a key regulator of intestinal mucosal immunity[J]. Life Sci, 2024, 345:122612. DOI: 10.1016/j.lfs.2024.122612 .
[26]	ZHENG S H, XUE T Y, WANG B, et al. Chinese medicine in the treatment of ulcerative colitis: the mechanisms of signaling pathway regulations[J]. Am J Chin Med, 2022, 50(7): 1781-1798. DOI: 10.1142/S0192415X22500756 .
[27]	YAO T, WU Y H, FU L Y, et al. Christensenellaceae minuta modulates epithelial healing via PI3K-AKT pathway and macrophage differentiation in the colitis[J]. Microbiol Res, 2024, 289:127927. DOI: 10.1016/j.micres.2024.127927 .
[28]	ACOSTA-MARTINEZ M, CABAIL M Z. The PI3K/Akt pathway in meta-inflammation[J]. Int J Mol Sci, 2022, 23(23): 15330. DOI: 10.3390/ijms232315330 .
[29]	ZHANG M, SONG X, LIU S B, et al. Magnolin inhibits intestinal epithelial cell apoptosis alleviating Crohn's disease-like colitis by suppressing the PI3K/AKT signaling pathway[J]. Int Immunopharmacol, 2024, 134: 112181. DOI: 10.1016/j.intimp. 2024.112181
[30]	王百乔, 林小茹, 韩敏, 等. 二甲双胍对阿尔茨海默症模型大鼠认知功能障碍及PI3K/Akt通路的影响[J]. 实验动物与比较医学, 2021, 41(4): 313-320. DOI:10.12300/j.issn.1674-5817.2020.185 .
	WANG B Q, LIN X R, HAN M, et al. Effects of metformin on cognitive dysfunction and PI3K/Akt pathway in Alzheimer's disease rats[J]. Lab Anim Comp Med, 2021, 41(4): 313-320. DOI:10.12300/j.issn.1674-5817.2020.185 .

泻白散对过敏性哮喘大鼠肺、肠组织形态结构及PI3K和Akt表达水平的影响

Effects of Xiebai San on the Morphological Structures of Lung and Intestinal Tissues and Expression Levels of PI3K and Akt in Rats with Allergic Asthma

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

图/表 9

参考文献 30

相关文章 15

编辑推荐

Metrics

本文评价

[1]	唐小杭, 谷颖敏, 吕阳阳, 黄明姝, 田雪松. 一种自研固定液用于制备大鼠眼球切片的组织学染色效果评价[J]. 实验动物与比较医学, 2026, 46(2): 261-270.
[2]	姜海涛, 袁韩涛, 黄雯婷, 杨蓉蓉, 陈晓春, 禹宝庆, 李四波. 腰舒逐瘀方通过miR-17-5P/MDM2/p53通路调控大鼠椎间盘纤维环细胞增殖与凋亡[J]. 实验动物与比较医学, 2026, 46(1): 55-65.
[3]	高超奇, 祝志波, 孙显东. 大鼠血管重构模型的应用进展与分类分析[J]. 实验动物与比较医学, 2025, 45(5): 542-550.
[4]	罗一凡, 张臻玮, 梅璐, 史叶萍, 邢艺彤, 张泽奇, 李楚欣, 韩春霞, 杨平顺, 陈秋生. 特络细胞介导肥胖症大鼠膏摩寡肽中草药复合制剂的减肥作用及其机制[J]. 实验动物与比较医学, 2025, 45(5): 551-560.
[5]	曹星新, 李艾亦, 侯婧涵, 李明学, 李艳艳, 靳玮华, 杨凤梅, 段素琴, 和占龙. 黄芪或其成分治疗急性胰腺炎的动物实验Meta分析[J]. 实验动物与比较医学, 2025, 45(5): 561-573.
[6]	秦超, 李双星, 赵婷婷, 蒋晨晨, 赵晶, 杨艳伟, 林志, 王三龙, 文海若. 药物安全评价用SD大鼠90 d喂养试验的背景数据研究[J]. 实验动物与比较医学, 2025, 45(4): 439-448.
[7]	刘力瑜, 嵇波, 刘小玄, 方洋, 张玲, 郭亭廷, 全烨, 李鹤文, 刘翼天. 大鼠胎儿期肺组织固定方法的探索[J]. 实验动物与比较医学, 2025, 45(4): 432-438.
[8]	肖林林, 杨逸萱, 黎珊杉, 罗兰诗雨, 尹思威, 孙俊铭, 施维, 欧阳轶强, 李习艺. 利用脑立体定位技术将人源三突变APP基因导入海马区构建阿尔茨海默病大鼠模型[J]. 实验动物与比较医学, 2025, 45(3): 269-278.
[9]	刘智伟, 杨然, 连浩, 张玉, 金立伦. 秦皮素对碘乙酸钠诱导骨关节炎模型大鼠的软骨保护与抗炎作用[J]. 实验动物与比较医学, 2025, 45(3): 259-268.
[10]	姜萌, 郝淑兰, 仝立国, 仲启明, 高振飞, 王永辉, 王晞星, 吉海杰. 长春瑞滨诱导大鼠足背静脉炎模型的动态评价[J]. 实验动物与比较医学, 2025, 45(3): 251-258.
[11]	潘颐聪, 蒋汶洪, 胡明, 覃晓. 慢性肾脏病大鼠主动脉钙化模型的术式优化及效果评价[J]. 实验动物与比较医学, 2025, 45(3): 279-289.
[12]	连辉, 姜艳玲, 刘佳, 张玉立, 谢伟, 薛晓鸥, 李健. 异常子宫出血大鼠模型的构建与评价[J]. 实验动物与比较医学, 2025, 45(2): 130-146.
[13]	罗世雄, 张赛, 陈慧. 常见哮喘动物模型的建立方法与评价研究进展[J]. 实验动物与比较医学, 2025, 45(2): 167-175.
[14]	孙效容, 苏丹, 贵文娟, 陈玥. 手术诱导大鼠中重度膝骨关节炎模型的建立与评价[J]. 实验动物与比较医学, 2024, 44(6): 597-604.
[15]	殷玉莲, 马丽娜, 屠思远, 陈玲, 叶媚娜, 陈红风. 非哺乳期乳腺炎大鼠模型的建立及评价[J]. 实验动物与比较医学, 2024, 44(6): 587-596.